Motus GI shares are trading higher after the company announced the Pure-Vu EVS Gastro was successfully used in the first procedure since receiving FDA clearance.
Portfolio Pulse from Benzinga Newsdesk
Motus GI announced that the Pure-Vu EVS Gastro was successfully used in the first procedure since receiving FDA clearance, leading to a rise in the company's shares.
November 10, 2023 | 1:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Motus GI's shares are trading higher following the successful first use of the Pure-Vu EVS Gastro since its FDA clearance.
The successful first use of the Pure-Vu EVS Gastro, following its FDA clearance, is a positive development for Motus GI. This could increase investor confidence in the company's product and its potential market success, leading to a rise in the company's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100